Affiliation:
1. Medical Physics Department The Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK
2. Department of Physics University of Liverpool Liverpool UK
Abstract
AbstractPurposeIn radiotherapy of the head and neck (H&N) it is common for the clinical target volume (CTV) to extend to the patient's skin. Adding a margin for set‐up uncertainty and delivery creates a planning target volume (PTV) that extends beyond the patient surface. This can result in excessive fluence being delivered to the build‐up region and therefore the skin. This study evaluates four different planning methods used when inverse‐planning H&N radiotherapy treatments with CTV extending to the skin. The aim of the study was to determine which planning method gives superior plan quality.MethodTen H&N cancer patients with a CTV contoured to the skin were inverse‐planned using four planning methods. The planning methods compared were: cropping the optimization PTV back from the skin surface by 5.0, 3.0, and 0.0 mm and a virtual bolus method. For each planning method, the increased fluence at the skin surface was analyzed. The CTV coverage and skin doses were compared. Plan robustness was evaluated by applying an isocenter shift of ±3.0 mm in the major axes.ResultsThe planning method cropping the PTV 0.0 mm from the skin surface results in an increased fluence in the build‐up region. The average volume of CTV receiving 98% of the prescription dose was 89.6% ± 3.4%, 91.6% ± 2.4%, and 93.5% ± 1.7% when cropped 5.0, 3.0, and 0.0 mm, respectively, and 93.4% ± 2.1% for the virtual bolus method. Introducing plan uncertainty affects CTV coverage the most when cropping 5.0 mm. When plan uncertainties are considered the methods of cropping 5.0, 3.0 mm, and the virtual bolus method have the same average skin dose within ±0.3%.ConclusionThis study shows that a virtual bolus planning method results in no increased fluence at the patient's surface, improves CTV coverage, and is the most robust to changes in setup and patient anatomy.
Reference19 articles.
1. NIMRAD QA Team. (2014).A randomised placebo‐controleed trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemotherapy or cetuximab. Radiotherapy planning delivery and QA guidelines version 1.1. Published online 2014:1‐80.
2. OwadallyW EvansM ParsonsE LeeJ BeasleyM.A Phase II /III trial of risk‐stratified reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human Papillomavirus (HPV) – positive oropharyngeal cancer Radiotherapy Outlining Planning Delivery and Quality Assurance G.2018;(August):1‐48.
3. MsbA GuidelinesR.Avelumab MSB0010718C Study B9991016 Radiation Guidelines (FINAL) 07October2016. (212):1‐12.